Compound Guide

MOTS-c

MOTS-c after the April 15 FDA reclassification — research on mitochondrial metabolism, dosing, safety, pricing, and how to source it through a pharmacy.

Last reviewed May 1, 2026

Quick Summary

What it is. MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) — a 16-amino-acid mitochondrial-derived peptide encoded by mitochondrial DNA, not nuclear DNA.

Most-studied research areas. Metabolic regulation, skeletal muscle mitochondrial bioenergetics, insulin sensitivity, exercise adaptation, age-related metabolic decline, and protection against cellular oxidative stress.

Current U.S. legal status (May 2026). On April 15, 2026, the FDA removed MOTS-c from Category 2 as part of a 12-peptide reclassification. It is now on an interim evaluation tier pending final 503A Bulks List placement at the July 23–24, 2026 PCAC meeting. Licensed compounding pharmacies may legally fill prescriptions under a valid practitioner order.

Expected post-PCAC compounded price. $120–$220 per 10mg vial at a legitimate compounding pharmacy.

Evidence base. Extensive preclinical research — over 200 indexed PubMed publications. Human clinical data is emerging but remains limited to observational studies and small cohorts. The mechanistic biochemistry is well-characterized; the translational evidence is still maturing.

What Is MOTS-c?

MOTS-c is a 16-amino-acid regulatory peptide encoded within the mitochondrial genome — a short open reading frame in the 12S rRNA region. This makes MOTS-c distinct from most therapeutic peptides: it is a mitochondrial-derived peptide (MDP), part of a small signaling family that includes humanin and SHLP1–6.

The discovery of MOTS-c and related MDPs changed the understanding of the mitochondrion. First reported by the Cohen research group at USC in 2015, MOTS-c established that mitochondria function not only as cellular power plants but also as endocrine signaling centers, producing peptides that circulate systemically and regulate whole-body metabolism.

MOTS-c has been detected in skeletal muscle, liver, adipose tissue, heart, and brain. Its levels are modulated by metabolic state: exercise, caloric restriction, and cold exposure all influence expression. Mechanistically, MOTS-c activates AMPK and PGC-1α, two central regulators of cellular energy metabolism, and influences the folate cycle and de novo purine biosynthesis to modulate glucose metabolism.

Unlike BPC-157 or TB-500 — which signal tissue repair — MOTS-c operates in metabolic regulation and energy homeostasis. This places it in a separate category for both research framing and therapeutic consideration.

What the Research Shows

Preclinical evidence is substantial

Published preclinical research — predominantly in mice, rats, and cell-based models — has established several well-replicated effects of exogenous MOTS-c administration:

Skeletal muscle mitochondrial function. A 2026 study (PMID: 41520850) demonstrated MOTS-c treatment augments muscle mitochondrial bioenergetics in a PGC-1α/AMPK-dependent manner, lowering ROS emission and oxidative stress damage.
Metabolic regulation and insulin sensitivity. One of the earliest replicated findings is improved glucose handling and insulin sensitivity in diet-induced obesity models.
Cardioprotection. MOTS-c mitigates myocardial ischemia-reperfusion injury (PMID: 41593376), attenuates cardiac dysfunction from high-altitude exposure via mitophagy (PMID: 41654147), and reduces diabetic myocardial fibrosis (PMID: 41710402).
Spermatogenesis. MOTS-c preserves spermatogenesis by suppressing ferroptosis through SLC7A11 (PMID: 41933740), with reduced serum levels found in patients with oligoasthenozoospermia.
Liver protection. MOTS-c protects against acetaminophen-induced liver injury (PMID: 41764620) and attenuates hyperoxia-induced bronchopulmonary dysplasia (PMID: 41802484).
Muscle atrophy. MOTS-c and humanin attenuate dexamethasone-induced muscle cell atrophy (PMID: 41732124).
Neuroprotection. Research demonstrated MOTS-c effects mediated through tetrahydrobiopterin and BDNF in a neurodevelopmental rat model (PMID: 41706383).

Human data is emerging but limited

As of May 2026, published large-scale randomized controlled trial data for MOTS-c in humans is absent. What exists includes:

Observational studies. Reduced serum MOTS-c levels have been found in women with PCOS (Scientific Reports PMID: 41680431, Arch Endocrinol Metab PMID: 41945630). Systemic MOTS-c increases paradoxically in obesity and remains unchanged after weight loss (PMID: 41551324). MOTS-c has been explored as a marker of treatment response in multiple myeloma (PMID: 41479490).
Exercise physiology. A human study (PMID: 41520850) found that despite increased interstitial MOTS-c during exercise, no arterio-venous difference was detected, suggesting skeletal muscle may not be the source of circulating MOTS-c — challenging earlier assumptions.
Sports medicine context. An April 2026 Sports Medicine review (PMID: 41966639) noted that “many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce.”

Where MOTS-c is most commonly discussed

In the practitioner community, MOTS-c generates the most interest for metabolic health optimization, age-related insulin sensitivity support, exercise performance research, and mitochondrial health protocols. It is less commonly discussed for acute injury indications.

Legal and Regulatory Status

Pre-April 15, 2026

Prior to the April 15 reclassification, MOTS-c was listed in Category 2 of the FDA’s 503A framework — effectively prohibiting licensed compounding pharmacies from preparing it at scale. Most consumer access came through unregulated “research chemical” vendors.

April 15, 2026 — Reclassification

On April 15, 2026, the FDA removed MOTS-c, along with 11 other peptides, from Category 2 and placed it on an interim evaluation tier. Licensed compounding pharmacies may now legally prepare MOTS-c under a valid prescription. The FDA has committed to a final 503A Bulks List placement decision at the July 23–24, 2026 PCAC meeting.

July 23–24, 2026 — PCAC Outlook

The Pharmacy Compounding Advisory Committee’s July 2026 meeting will recommend final placement for MOTS-c. The compound’s strong mechanistic grounding and over 200 indexed PubMed publications provide a substantial evidence foundation. However, the relative scarcity of human clinical trial data compared to BPC-157 or KPV may lead PCAC to recommend a restricted or conditional placement rather than unrestricted approval. Industry expectation is that MOTS-c will move forward but potentially with continuing evaluation requirements.

We will update this page within 72 hours of the PCAC outcome. Subscribers to the PeptidesBeat Daily Brief receive regulatory updates in real time.

State-level variance

Federal reclassification sets the floor; state pharmacy boards can set tighter rules. California, New York, Massachusetts, Connecticut, Illinois, Maryland, New Jersey, Hawaii, Vermont, and DC maintain more restrictive non-resident pharmacy regimes — expect extra verification steps in those states. See the state-by-state tracker for your jurisdiction.

The research-chemical channel remains outside the law

The April 15 action clarifies the prescription pathway. It does not legitimize the gray market. MOTS-c purchased from a research-chemical vendor labeled “not for human consumption” is still operating outside the legal drug supply chain — regardless of the federal reclassification. Customs enforcement of peptide imports has tightened visibly in 2025–2026.

How MOTS-c Is Typically Administered

Important: Nothing below is a dosing recommendation. Route of administration, dose, frequency, and duration are prescriber-determined. This section describes what practitioners report as typical practice, not a protocol.

MOTS-c is most commonly administered by subcutaneous injection into the abdominal region, rotated between sites. The peptide is supplied as lyophilized powder and must be reconstituted with bacteriostatic water. Practitioners typically prescribe short courses of 4–8 weeks, followed by a break of equivalent duration.

Oral administration of MOTS-c is not established in the literature; injectable administration is the standard.

Reported Safety Signals

Across the preclinical literature, MOTS-c has a favorable short-term safety profile in animal models. Reported mild effects include transient injection-site reactions and, less commonly, mild gastrointestinal effects.

Theoretical considerations include the potential for MDPs to influence pathways involved in cellular proliferation — warranting screening for active or recent malignancy, as experienced prescribers apply across the peptide category.

Long-term human safety data is effectively absent. This limitation applies to the entire practitioner-peptide category. Proceed under licensed practitioner supervision; disclose your full medical history.

One study (PMID: 41551324) found systemic MOTS-c levels increased paradoxically in adults with obesity — suggesting the endogenous signaling response to metabolic stress is complex. This underscores the importance of working with a practitioner who understands the compound’s metabolic context.

Expected Pricing (Post-PCAC)

Format	Expected price range
10mg vial (lyophilized, for reconstitution)	$120–$220
5mg vial (lyophilized)	$70–$130
Reconstituted ready-to-use (10mg)	$160–$260
4-week course (typical practitioner protocol)	$200–$400

Research-chemical vendors price 40–60% lower. That delta does not reflect efficiency — it reflects the absence of sterility testing, potency verification, third-party COAs, and pharmacist oversight. Independent testing of gray-market peptides has shown substantial purity and endotoxin variability.

How to Source It Legitimately

The prescription pathway, step by step:

Establish a relationship with a peptide-familiar prescriber. This can be an MD, DO, NP, or PA, depending on state regulations. Telehealth is acceptable in most permissive and moderate-tier states; confirm eligibility with the prescriber before booking.
Have a documented clinical rationale. Licensed prescribers need a clinical basis for the prescription. MOTS-c is not an “I want to try it” compound — it is prescribed in the context of documented metabolic or mitochondrial health concerns evaluated through standard clinical assessment.
Identify a legitimate compounding pharmacy licensed in your state. Use our vetted compounding pharmacy directory. Confirm the pharmacy holds current licensure in both its home state and yours. Apply the 10-point pharmacy checklist before placing an order.
Request a Certificate of Analysis for your specific batch, not a generic example. A legitimate compounder provides this without hesitation.
Verify shipping and cold-chain. MOTS-c should ship with cold packs. A package that arrives warm has been compromised.
Maintain your supervision relationship. Report any unexpected symptoms to your prescriber.

This legal path is slower and more expensive than the gray market. It is also the only legal, verifiable path integrated with your medical care.

Common Questions

Is MOTS-c FDA approved?

No. MOTS-c is not an FDA-approved drug for any indication. The April 15, 2026 action removed it from Category 2 (prohibited for compounding), which allows licensed compounding pharmacies to prepare it under prescription. This is a different regulatory status than FDA approval, which requires demonstrated safety and efficacy in large-scale human clinical trials.

Is MOTS-c legal in my state?

Federal reclassification permits compounding nationwide, but state pharmacy board rules vary. Ten states and DC maintain more restrictive regimes that add verification steps. See our state-by-state tracker for your specific jurisdiction.

Is MOTS-c safe?

The short-term reported safety profile in preclinical research and limited human observation is favorable. Long-term human safety data is limited. Standard practice is supervision by a licensed clinician who has screened for contraindications and who monitors the course.

What is the difference between MOTS-c and BPC-157?

MOTS-c is a mitochondrial-derived peptide involved in metabolic regulation. BPC-157 is a synthetic peptide derived from gastric protein, studied for soft-tissue healing. Their mechanisms and primary indications are distinct. See our BPC-157 pillar guide.

What is the difference between MOTS-c and GHK-Cu?

MOTS-c is a mitochondrial signaling peptide focused on metabolic regulation. GHK-Cu is better characterized in human studies; MOTS-c has stronger preclinical mechanistic support. See our GHK-Cu pillar guide.

Can MOTS-c help with weight loss?

Preclinical research shows MOTS-c improves glucose tolerance and insulin sensitivity in diet-induced obesity models — but weight changes appear secondary to metabolic improvements rather than direct appetite suppression. The sports medicine review (PMID: 41966639) cautions that animal model outcomes frequently do not replicate in human trials.

Can I buy MOTS-c online without a prescription?

You can find online vendors selling MOTS-c as a “research chemical.” This path is not legal for human use, frequently supplies contaminated or underpotent product, and leaves you without a clinician of record. We actively recommend against it. The legal path is prescription plus compounding pharmacy.

Does MOTS-c show up on drug tests?

MOTS-c is not included on standard employment or athletic drug screens. However, it may be captured by specialized sports-anti-doping testing. WADA-affiliated athletes should assume MOTS-c use carries sport-specific risk.

Does MOTS-c work for longevity?

The mechanistic rationale — improving mitochondrial bioenergetics, reducing oxidative stress — is compelling, and animal models show healthspan extension. However, no published human trial has demonstrated a longevity effect. See our 2026 Peptide Law Playbook for evaluating peptide claims.

What about MOTS-c and exercise?

Exercise modulates endogenous MOTS-c levels, and exogenous MOTS-c appears to influence muscle mitochondrial function (PMID: 41520850). However, the same study found skeletal muscle may not be the source of circulating MOTS-c during exercise — suggesting exercise-induced elevation may originate from other tissues. This is an active research area with unresolved questions.

Where should I start if I’m considering MOTS-c?

Three steps. First, read the 2026 Peptide Law Playbook for the full context on the regulatory landscape. Second, find a peptide-familiar prescriber in your state through our provider directory. Third, apply the 10-point pharmacy checklist before placing any order. In that order.

BPC-157 — Different biological domain (tissue repair vs. metabolic regulation); sometimes used alongside MOTS-c in recovery protocols.
GHK-Cu — Copper-binding tripeptide with tissue repair properties; compared with MOTS-c on research-evidence maturity.
TB-500 — Thymosin beta-4 fragment; primarily studied for soft-tissue recovery and systemic repair signaling.